On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer.

PURPOSE Clear and accurate information about health related quality of life outcomes for men diagnosed with prostate cancer is essential for men and their physicians to make appropriate care decisions. To determine the completeness and quality of available health related quality of life information we performed a review of health related quality of life studies, assessing what information was and was not reported. MATERIALS AND METHODS A structured literature search identified 184 relevant health related quality of life studies representing 40,931 subjects. RESULTS More than 95% of health related quality of life studies did not provide key information about factors known to influence outcomes. The most common omissions included information about treatments received, followup, socioeconomic status or demographic characteristics. Most data were obtained from well educated, high income socioeconomic groups, who are generally quite healthy. More than 60% of subjects were college graduates, 85% were currently married and 43% were currently employed. While black Americans comprised 15% of men studied in the 80% of studies reporting race, little information is available on Hispanic or Asian men. CONCLUSIONS Most of the available prostate cancer health related quality of life literature does not describe or does not account for factors known to influence health outcomes. These omissions limit their interpretability for patients trying to make decisions about treatment. More attention should be given to fully characterizing all dimensions of care that may influence quality of life outcomes and evaluating health related quality of life in Asian and Hispanic populations. Men and physicians should exercise caution when interpreting results that do not fully account for multiple factors that influence health related quality of life.

[1]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[2]  M. Barry,et al.  Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000. , 2004, Journal of the National Cancer Institute. Monographs.

[3]  D. Lubeck,et al.  Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. , 1999, Urology.

[4]  J Kievit,et al.  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  B. Given,et al.  Physical Functioning and Depression Among Older Persons with Cancer , 2001 .

[6]  D. Lubeck,et al.  Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. , 2001, The Journal of urology.

[7]  J. Coebergh,et al.  Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. , 1999, Journal of clinical epidemiology.

[8]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[9]  E. Klein,et al.  Sexuality and Health-Related Quality of Life After Prostate Cancer in African-American and White Men Treated for Localized Disease , 2004, Journal of sex & marital therapy.

[10]  John T. Wei,et al.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer. , 2004, The Journal of urology.

[11]  J. Johansson,et al.  Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. , 1998, Urology.

[12]  K. Armstrong,et al.  Development and testing of the health care system distrust scale , 2007, Journal of General Internal Medicine.

[13]  S. Madersbacher,et al.  Frequent use of complementary medicine by prostate cancer patients. , 2003, European urology.

[14]  John T. Wei,et al.  Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. , 2003, The Journal of urology.

[15]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Lubeck,et al.  Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. , 2002, The Journal of urology.

[17]  Ruth Etzioni,et al.  Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. , 2004, Urology.

[18]  G. Naglie,et al.  30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. , 2005, Journal of the National Cancer Institute.

[19]  E. Giovannucci,et al.  The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patients , 2002, Cancer.

[20]  D. Kuban,et al.  Quality of life after treatment for localized prostate cancer: differences based on treatment modality. , 2001, The Journal of urology.

[21]  S H Kaplan,et al.  Development and testing of a new measure of case mix for use in office practice. , 1995, Medical care.

[22]  C. Ashton,et al.  Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  V. Helgeson,et al.  Early quality of life in patients with localized prostate carcinoma , 2001, Cancer.

[24]  J. Stanford,et al.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.

[25]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[26]  W. Catalona,et al.  Quality‐of‐life outcomes for men with prostate carcinoma detected by screening , 2000, Cancer.

[27]  R A Stephenson,et al.  Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.

[28]  R. Heinrich,et al.  Development of a comprehensive quality of life measurement tool: CARES. , 1990, Oncology.

[29]  A. Zwinderman,et al.  A Prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients , 2004, The Prostate.

[30]  P. F. Short,et al.  Income Disparities in the Quality of Life of Cancer Survivors , 2006, Medical care.

[31]  Srinivasan Vijayakumar,et al.  Prostate cancer, race, and socioeconomic status: Inadequate adjustment for social factors in assessing racial differences , 1996, The Prostate.

[32]  K. Yoshimura,et al.  Neoadjuvant flutamide monotherapy for locally confined prostate cancer , 2003, International journal of urology : official journal of the Japanese Urological Association.

[33]  Per Carlsson,et al.  The estimated economic value of the welfare loss due to prostate cancer pain in a defined population , 2004, Acta oncologica.

[34]  R H Brook,et al.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.

[35]  O. Brawley,et al.  Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Coebergh,et al.  Quality of life among long-term breast cancer survivors: a systematic review. , 2005, European journal of cancer.

[37]  I. Thompson,et al.  Association of African-American ethnic background with survival in men with metastatic prostate cancer. , 2001, Journal of the National Cancer Institute.

[38]  F. Meyers,et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Lubeck,et al.  The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. , 2001, Journal of clinical epidemiology.

[40]  P Carlsson,et al.  A population-based study of pain and quality of life during the year before death in men with prostate cancer , 2004, British Journal of Cancer.

[41]  W. Catalona,et al.  Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. , 1999, The Journal of urology.

[42]  P. Iyer,et al.  Comparative study of the clinical efficacy of two dosing regimens of flutamide. , 1999, Molecular urology.

[43]  M. Litwin,et al.  Health-Related Quality-of-Life in Low-Income, Uninsured Men with Prostate Cancer , 2005, Journal of health care for the poor and underserved.

[44]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[45]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[46]  V. Shavers,et al.  Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.

[47]  T. Tammela,et al.  A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.

[48]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.